Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12151
Abstract: Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi‐resistant melanoma (BR) cells are vulnerable to… read more here.
Keywords: melanoma cells; arginine deprivation; degradation ampk;